Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours Β· Estimated delivery Aug 19 - Aug 24
Contact your healthcare provider promptly if you experience any of the following after injection: significant swelling or hardness at the injection site that does not resolve within 48 hours, redness that expands beyond two inches from the injection point, warmth or heat radiating from the injection site combined with pain, any discharge from the injection site including pus or cloudy fluid, fever following injection, severe allergic reaction signs including hives or difficulty breathing, or persistent pain that intensifies rather than improving over 24 hours
Individuals with moderate to severe diabetic retinopathy, long diabetes duration, or poor prior glycaemic control face elevated risk during initial treatment months
The elevation is dose-dependent up to a saturation point, which research places at approximately 1 mcg per kilogram of body weight per injection
This information is invaluable when you have follow-up consultations with your healthcare provider
Baseline bone density testing is not routinely required for all patients but may be appropriate for those at higher risk, including postmenopausal women, older adults, individuals with prior fractures, or those with documented osteopenia or osteoporosis
Secondly, GLP-1 receptor agonists carry important safety considerations including risk of pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (based on rodent studies, though human relevance remains uncertain)
